New consensus statement will take into account latest clinical trial evidence on renal denervation


A new consensus statement—in development from the European Society of Cardiology (ESC) and the European Association of Cardiovascular Interventions (EAPCI)—will take into account latest evidence of the safety and efficacy of renal denervation as a device-based treatment from sham controlled trials.

This was among the messages from Michel Azizi (Hôpital Européen Georges Pompidou, Paris, France), the co-primary investigator with Ajay Kirtane (Columbia University Irving Medical Center, New York, USA) in the RADIANCE-HTN TRIO (on-medications) and RADIANCE-HTN SOLO (initially off-medications) clinical studies examining the efficacy and safety of endovascular ultrasound renal denervation with the Paradise catheter (Recor Medical) in subjects with uncontrolled hypertension.

During EuroPCR 2022 (17–20 May, Paris, France), patient-level pooled analysis of ultrasound renal denervation in RADIANCE-HTN SOLO and TRIO trials was presented by Kirtane, pointing to advantages in both blood pressure reduction and medication burden decrease across the pooled renal denervation patient population when compared to sham treatment.

In this interview, Michel Azizi discusses the results, which he says increase the evidence around the mid-term efficacy of using renal denervation with an ultrasound renal denervation catheter, as well as its safety.


Please enter your comment!
Please enter your name here